In the early 60s of the 20th century the world’s scientists came to the conclusion that double-stranded ribonucleic acids (dsRNA) are very effective against viral infections and for the immune system correction.
On the basis of these discoveries several groups of scientists in different countries around the world started medical product development. As a result, a number of worldwide known preparations has been developed.
One of these groups of scientists under the direction of the Doctor of Medicine Guna Feldmane began work on the development of the pharmaceutical product Larifan in the Latvian Institute of Microbiology and Virology in Riga.
Each group of scientists went a different way in developing a variety of dsRNA obtaining techniques, both from natural sources and by chemical synthesis. The Latvian group of scientists chose the biotechnological way of dsRNA production. As a result, in Esherichia coli bacteria an original antiviral pharmaceutical product Larifan was created.
Larifan possesses multiple biological activities like interferon-inducing, immunomodulating, antiviral, antitumoral and antimutagenic properties. These activities are as result of the action of induced endogenous interferon or may be provoked directly by the dsRNA molecule as well.
The method of manufacturing dsRNA Larifan is patented. Since 1997 it has been produced ar Larifans Ltd. in Latvia.